Supintelligence: To Ban or Not to Ban? Max Tegmark & Dean Ball join Liron Shapira on Doom Debates

What It Covers

MIT professor Max Tegmark and White House AI adviser Dean Ball debate whether superintelligence should be banned on the Doom Debates podcast hosted by Liron Shapira. Tegmark argues for FDA-style preemptive safety standards before any superintelligent system launches, while Ball contends reactive regulation and liability systems are sufficient, with their PDoom estimates diverging dramatically at 90%+ versus 0.01%.

Key Questions Answered

• •PDoom Divergence: Max Tegmark places probability of catastrophic loss of control at over 90% without binding AI regulation, citing MIT research showing recursive scalable oversight fails 92% of the time in their most optimistic modeling scenario. Dean Ball estimates 0.01% — a figure he later acknowledged was improvised — reflecting a fundamental disagreement not just on policy but on whether the extinction-scale threat is mechanically coherent enough to warrant serious probability assignment.
• •Regulatory Framing Shift: Rather than defining and banning "superintelligence" in statute — which risks banning beneficial systems — Tegmark proposes banning specific outcomes: bioweapon assistance, overthrow of government, uncontrollable autonomous behavior. This shifts the burden of proof to companies to demonstrate safety, mirroring how the FDA requires drug makers to quantify harms and benefits rather than regulators pre-specifying every dangerous molecule.
• •Two Separate AI Races: Tegmark distinguishes between the race for economic and military AI dominance — which controllable AI tools can win — and the race to build uncontrollable superintelligence, which he calls a "suicide race." Conflating these two races is the primary rhetorical mechanism used by AI lobbyists in Washington to argue against any binding regulation, framing all safety standards as conceding ground to China.
• •China's Self-Interest in Control: Tegmark argues China will not permit any domestic company to build uncontrollable superintelligence because the CCP values its own political survival above AI capability gains. He cites a 2023 Elon Musk meeting with senior CCP officials where Musk noted superintelligence would mean China is run by the AI, not the CCP — prompting visible alarm and China's first AI regulations within weeks.
• •The Thalidomide Regulatory Model: Tegmark uses thalidomide — which caused over 100,000 birth defects before being pulled — to argue that companies cannot self-certify safety for novel powerful systems. The correct regulatory model is not to pre-define every harm, but to require companies to run structured trials, quantify side effects, and present findings to independent experts without financial conflicts of interest before deployment.
• •Ball's Evolution on O1-Class Models: Ball describes changing his risk calculus after OpenAI released o1, which introduced system-two deliberative reasoning and produced measurable capability jumps in biology, mathematics, and cybersecurity. He now supports targeted regulation for catastrophic bio and cyber risks — and backed California's SB 53 — but draws a line at broad preemptive licensing regimes, arguing they lock in assumptions before sufficient empirical experience exists.
• •Safety Spending Gap: Tegmark contrasts AI lab safety budgets — roughly 1% of total spend — with pharmaceutical companies like Novartis and Pfizer, which allocate substantially more to clinical trials because regulatory requirements create direct financial incentives. He argues that once binding AI safety standards exist, companies will compete to meet them fastest, transforming safety researchers from perceived blockers into competitive assets, as occurs in pharma.